These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 28697809)

  • 1. Comparison of HCV viral load and its genotype distributions in HCV mono- and HIV/HCV co-infected illicit drug users.
    Jamalidoust M; Namayandeh M; Moghadami M; Ziyaeyan M
    Virol J; 2017 Jul; 14(1):127. PubMed ID: 28697809
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of HIV infection in patients infected with chronic HCV (genotypes 1a and 3a): virological and clinical changes.
    Behzadpour D; Ahmadi Vasmehjani A; Mousavi Nasab SD; Ahmadi NA; Baharlou R
    Pathog Glob Health; 2016; 110(7-8):310-315. PubMed ID: 27830997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HCV genotype analysis in HCV-HIV-co-infected Puerto Ricans who are injecting drug users: undetermined and mixed infections.
    Ríos-Olivares E; Yamamura Y; Gómez MA; Guzmán L; Rodríguez N; Fernández D; Hunter Mellado R
    Cell Mol Biol (Noisy-le-grand); 2001 Sep; 47(6):1017-24. PubMed ID: 11785651
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial.
    Sulkowski M; Hezode C; Gerstoft J; Vierling JM; Mallolas J; Pol S; Kugelmas M; Murillo A; Weis N; Nahass R; Shibolet O; Serfaty L; Bourliere M; DeJesus E; Zuckerman E; Dutko F; Shaughnessy M; Hwang P; Howe AY; Wahl J; Robertson M; Barr E; Haber B
    Lancet; 2015 Mar; 385(9973):1087-97. PubMed ID: 25467560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HCV RNA decline in chronic HCV genotype 2 and 3 during standard of care treatment according to IL28B polymorphism.
    Stenkvist J; Sönnerborg A; Weiland O
    J Viral Hepat; 2013 Mar; 20(3):193-9. PubMed ID: 23383658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utility of week-4 viral response to tailor treatment duration in hepatitis C virus genotype 3/HIV co-infected patients.
    Crespo M; Esteban JI; Ribera E; Falco V; Sauleda S; Buti M; Esteban R; Guardia J; Ocaña I; Pahissa A
    AIDS; 2007 Feb; 21(4):477-81. PubMed ID: 17301566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Higher levels of hepatitis C virus RNA found in blood donors co-infected with HIV as compared to HCV mono-infected donors.
    Alidjinou EK; Moukassa D; Ebatetou-Ataboho E; Mahoungou GH; Pambou JP; Sané F; Prevost B; Bocket L; Ibara JR; Hober D
    J Infect Dev Ctries; 2014 Aug; 8(8):1068-71. PubMed ID: 25116677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of hepatitis C in HCV mono-infected and in HIV-HCV co-infected patients: an open-labelled comparison study.
    Gonvers JJ; Heim MH; Cavassini M; Müllhaupt B; Genné D; Bernasconi E; Borovicka J; Cerny A; Chave JP; Chuard C; Dufour F; Dutoit V; Malinverni R; Monnat M; Negro F; Troilliet N; Oneta C
    Swiss Med Wkly; 2010; 140():w13055. PubMed ID: 20648398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HCV non-1b genotypes in injecting drug users from Romania.
    Ruta S; Sultana C; Oprea C; Vagu C; Ceausu E; Cernescu C
    J Infect Dev Ctries; 2016 May; 10(5):523-7. PubMed ID: 27249529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The distinct epidemic characteristics of HCV co-infection among HIV-1-infected population caused by drug injection and sexual transmission in Yunnan, China.
    Zhang AM; Yang M; Gao L; Zhang M; Jiao L; Feng Y; Dong X; Xia X
    Epidemiol Infect; 2019 Sep; 147():e261. PubMed ID: 31475647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C.
    Martin-Carbonero L; Nuñez M; Mariño A; Alcocer F; Bonet L; García-Samaniego J; López-Serrano P; Cordero M; Portu J; Soriano V
    AIDS; 2008 Jan; 22(1):15-21. PubMed ID: 18090387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors related to the chronicity and evolution of hepatitis C infection in patients co-infected by the human immunodeficiency virus.
    Pérez-Cano R; Fernández-Gutiérrez C; López-Suárez A; Mira J; Girón-González JA
    Clin Microbiol Infect; 2002 Sep; 8(9):589-97. PubMed ID: 12427219
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study.
    Molina JM; Orkin C; Iser DM; Zamora FX; Nelson M; Stephan C; Massetto B; Gaggar A; Ni L; Svarovskaia E; Brainard D; Subramanian GM; McHutchison JG; Puoti M; Rockstroh JK;
    Lancet; 2015 Mar; 385(9973):1098-106. PubMed ID: 25659285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of control selection on sustained viral response rates in genotype 2/3 HCV mono-infected versus HIV/HCV co-infected patients.
    Nilsson J; Weiland O
    Scand J Infect Dis; 2010 Jul; 42(6-7):533-9. PubMed ID: 20214543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High prevalence of occult hepatitis C virus infection in injection drug users with HIV infection.
    Donyavi T; Bokharaei-Salim F; Khanaliha K; Sheikh M; Bastani MN; Moradi N; Babaei R; Habib Z; Fakhim A; Esghaei M
    Arch Virol; 2019 Oct; 164(10):2493-2504. PubMed ID: 31346769
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short communication: atazanavir-based therapy is associated with higher hepatitis C viral load in HIV type 1-infected subjects with untreated hepatitis C.
    Rivero-Juarez A; Mira JA; Santos-Gil I; Lopez-Cortes LF; Girón-Gonzalez JA; Marquez M; Merino D; Tellez F; Caruz A; Pineda JA; Rivero A;
    AIDS Res Hum Retroviruses; 2013 Feb; 29(2):223-5. PubMed ID: 22966845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment of chronic hepatitis C in human immunodeficiency virus infected patients].
    Begovac J; Romih V
    Acta Med Croatica; 2009 Dec; 63(5):423-9. PubMed ID: 20198902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determining hepatitis C virus genotype distribution among high-risk groups in Iran using real-time PCR.
    Jamalidoust M; Namayandeh M; Asaei S; Aliabadi N; Ziyaeyan M
    World J Gastroenterol; 2014 May; 20(19):5897-902. PubMed ID: 24914351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis C virus infection among injection drug users with and without human immunodeficiency virus co-infection.
    Hsieh MH; Tsai JJ; Hsieh MY; Huang CF; Yeh ML; Yang JF; Chang K; Lin WR; Lin CY; Chen TC; Huang JF; Dai CY; Yu ML; Chuang WL
    PLoS One; 2014; 9(4):e94791. PubMed ID: 24722534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis C virus populations in the plasma, peripheral blood mononuclear cells and cerebrospinal fluid of HIV/hepatitis C virus-co-infected patients.
    Bagaglio S; Cinque P; Racca S; Pedale R; Grasso MA; Lazzarin A; Morsica G
    AIDS; 2005 Oct; 19 Suppl 3():S151-65. PubMed ID: 16251813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.